BIOMAT Database Logo BIOMAT Database Logo

Use of Prograf (FK 506) as rescue therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993

G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
Baylor University Medical Center, Dallas, Texas.

This report describes the clinical characteristics and demographics of patients enrolled into this rescue trial for patients experiencing refractory rejection after liver transplantation. Actuarial graft and patient survival at 12 months postconversion was 50% and 72%, respectively. Actual treatment success at 3 months postconversion was 70%. Karnofsky scores and liver function tests were significantly improved for patients continuing on therapy indicating clinical benefit in these patients. The safety profile of FK 506 is acceptable for such a high-risk group of patients. These preliminary clinical results support the conclusion that FK 506 can effectively control and reverse refractory rejection in a majority of liver transplantation patients.

UI MeSH Term Description Entries
D008111 Liver Function Tests Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function
D008297 Male Males
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003141 Communicable Diseases An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host. Infectious Diseases,Communicable Disease,Disease, Communicable,Disease, Infectious,Diseases, Communicable,Diseases, Infectious,Infectious Disease
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses

Related Publications

G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
FK 506 used as rescue therapy for refractory liver allograft rejection.
August 1994, Transplantation proceedings,
G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
FK 506 rescue therapy for refractory acute rejection in five liver recipients.
December 1991, Transplantation proceedings,
G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
FK 506 rescue therapy for intractable liver allograft rejection.
January 1994, Transplant international : official journal of the European Society for Organ Transplantation,
G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
August 1996, Clinical transplantation,
G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
Use of FK 506 for treatment of chronic rejection after liver transplantation.
December 1991, Transplantation proceedings,
G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
April 1996, Transplantation proceedings,
G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
FK 506 treatment of intractable rejection after liver transplantation.
August 1993, Transplantation proceedings,
G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients.
December 1991, Transplantation proceedings,
G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group.
February 1995, Transplantation proceedings,
G B Klintmalm, and R Goldstein, and T Gonwa, and R H Wiesner, and R A Krom, and B W Shaw, and R Stratta, and N L Ascher, and J W Roberts, and J Lake
Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group.
February 1995, Transplantation proceedings,
Copied contents to your clipboard!